Abstract
Mesangial proliferative glomerulonephritis (MsPGN), the most common pathological type of primary glomerular disease, is characterized by diffuse glomerular mesangial cell proliferation, inflammatory response, and varying degrees of mesangial matrix expansion, which often leads to end-stage renal disease. Despite a combined treatment with glucocorticoids, immunosuppressants, antiplatelet agents, and antilipidemic drugs is effective in treating MsPGN, the treatment duration is long and the efficacy is poor. In the book Modern Practical Chinese Medicines, an herbal formula Da-Yu-Gong Decoction (DYGD) consisting of Rhei Radix et Rhizoma (dried roots and rhizomes of Rheum palmatum L.) and Rosae Multiflorae Fructus (dried fruits of Rosa multiflora Thunb.) is documented for treating nephritis. To our knowledge, there is no pharmacological basis for this clinical application of DYGD. This study aimed to investigate the anti-MsPGN effects and mechanisms of an extract of DYGD.
Griess assay results showed that among different DYGD extracts, the ethyl acetate extract (hereafter refer to as DYGDE) had the most potent effect in inhibiting nitric oxide (NO) release from RAW264.7 cells. MTT assays showed that DYGDE had a dose-dependent inhibitory effect on PDGF-BB-stimulated proliferation of human HRMC glomerular mesangial cells and rat HBZY- 1glomerular mesangial cells. RT-qPCR results showed that DYGDE was capable of inhibiting the up-regulation of cyclin D2, collagen-1, and α-SMA in PDGF-BB-stimulated HRMC or HBZY-1 cells. Analyses of GSE93798 and GSE14795 datasets from Gene Expression Omnibus (GEO) coupled with network pharmacology analysis revealed that C-type lectin receptor signaling pathway and the Leukocyte transendothelial migration pathway were potentially involved in the anti-MsPGN effects of the formula, which warrant further investigations. Our findings are expected to provide pharmacological justifications for the use of DYGD in treating MsPGN.
Griess assay results showed that among different DYGD extracts, the ethyl acetate extract (hereafter refer to as DYGDE) had the most potent effect in inhibiting nitric oxide (NO) release from RAW264.7 cells. MTT assays showed that DYGDE had a dose-dependent inhibitory effect on PDGF-BB-stimulated proliferation of human HRMC glomerular mesangial cells and rat HBZY- 1glomerular mesangial cells. RT-qPCR results showed that DYGDE was capable of inhibiting the up-regulation of cyclin D2, collagen-1, and α-SMA in PDGF-BB-stimulated HRMC or HBZY-1 cells. Analyses of GSE93798 and GSE14795 datasets from Gene Expression Omnibus (GEO) coupled with network pharmacology analysis revealed that C-type lectin receptor signaling pathway and the Leukocyte transendothelial migration pathway were potentially involved in the anti-MsPGN effects of the formula, which warrant further investigations. Our findings are expected to provide pharmacological justifications for the use of DYGD in treating MsPGN.
| Original language | English |
|---|---|
| Publication status | Published - 16 Aug 2024 |
| Event | 23rd International Conference of the Modernization of Chinese Medicine & Health Products - Hong Kong Convention and Exhibition Centre, hybrid, Hong Kong Duration: 15 Aug 2024 → 16 Aug 2024 https://icmcm.hktdc.com/pdf/2024/Conference_eBooklet/e-booklet.pdf (Conference Abstract) https://mcmia.org/en/icmcm-2024/ (Conference website) https://drive.google.com/file/d/1t7dmhJ1jm3SwLZcnjP3433yESQs49mWJ/view?usp=sharing (Conference programme) |
Conference
| Conference | 23rd International Conference of the Modernization of Chinese Medicine & Health Products |
|---|---|
| Abbreviated title | ICMCM 2024 |
| Country/Territory | Hong Kong |
| City | hybrid |
| Period | 15/08/24 → 16/08/24 |
| Internet address |
|
